By LAURAN NEERGAARD and MATTHEW PERRONE Associated Press
Share this story

Federal health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the U.S. weighs beginning vaccinations in youngsters.

Start Free AccountGet access to 7 premium stories every month for FREE!
Already a Subscriber?Current print subscriber? Activate your complimentary Digital account.
Subscribe NowChoose a package that suits your preferences.